EXEL Stock Slides After FDA Adds Three Months To Cancer Drug Review — William Blair Sees More Swings In Near Term
Shares of Exelixis (EXEL) fell 2% on Friday after the company said U.S. regulators added three months to the review of its next cancer drug, but William Blair still sees a low chance of an outright rejection.The Food and Drug Administration told Exelixis on Thursday that it had extended the review…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.